Vipergen Publishes Review on the Expanding Role of Chemical Libraries in Next-Generation Drug Discovery
Vipergen senior scientist Tobias N. Hansen and CEO Nils J. V. Hansen have authored a review, Contemporary Applications of Chemical Libraries for Drug Discovery and Methods for their Synthesis, highlighting how modern chemical libraries are helping researchers exploring chemical space more effectively in the search for new drug candidates. The paper now published in ChemistryEurope, outlines practical ways to design, compare, and select libraries for different discovery challenges, with a focus on how molecular diversity can be measured and built into screening collections.
The review covers both traditional small-molecule screening collections and newer affinity-selection formats, including DNA-encoded libraries (DELs), peptide-encoded libraries, and self-encoded libraries. It also examines synthetic strategies such as diversity-oriented synthesis, biology-oriented synthesis, and late-stage skeletal edition, showing how advances in chemistry continue to expand the scope of compounds available for drug discovery.
A key message of the paper is that library quality matters as much as, or more than, library size. Looking ahead, the authors points to improved library purity, broader encoded chemistry, stronger computational workflows, and incorporation of AI as important drivers for the next generation of drug discovery.
The review is published in ChemistryEurope, the new flagship journal of the Chemistry Europe publishing association. The journal is open to all, hereby serving the global community with an open-access platform for exciting discoveries.
Find the paper here
About Vipergen:
Vipergen is a world-leading provider of small-molecule drug discovery services based on DNA-encoded library (DEL) technologies and is the first and only company capable of screening DELs inside a living cell. Vipergen provides its proprietary suite of leading-edge DEL technologies through funded discovery partnerships with leading pharmaceutical and biotechnology companies, including top pharmaceutical companies in the U.S., EU, and Japan. For more details about Vipergen and the YoctoReactor® (yR), Binder Trap Enrichment® (BTE), and Cellular Binder Trap Enrichment® (cBTE) drug discovery technology platforms, please visit www.vipergen.com.